Wegovy vs Mounjaro 2026: Which GLP-1 Is Better for Weight Loss?
Reviewed against the SURMOUNT-5 head-to-head trial (NEJM, May 2025), STEP-1 (NEJM, 2021), SURMOUNT-1 (NEJM, 2022), and current FDA labeling as of May 2026.
Mounjaro produces more weight loss. Wegovy has the FDA weight-loss approval and a proven cardiovascular benefit. Your insurance and goals decide.
The honest answer: Mounjaro (tirzepatide) is the more potent molecule for weight loss based on SURMOUNT-5. But Wegovy (semaglutide) has the explicit FDA approval for chronic weight management, a proven cardiovascular benefit from the SELECT trial, and is cheaper in compounded form. Many patients use Mounjaro off-label for weight loss or get Zepbound (same molecule, weight-loss label) instead.
Wegovy vs Mounjaro: Head-to-Head At A Glance
| Factor | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Drug class | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA-approved for weight loss? | Yes (chronic weight management + CV risk) | No (T2D only; Zepbound is the weight-loss brand) |
| Avg weight loss (SURMOUNT-5, 72 wk) | -13.7% | -20.2% |
| Dosing frequency | Once weekly injection | Once weekly injection |
| Dose range | 0.25mg → 2.4mg (new 7.2mg approved March 2026) | 2.5mg → 15mg |
| Top side effect (clinical trials) | Nausea ~44% | Nausea 24-33% |
| List price (May 2026) | ~$1,349/4 weeks | ~$1,086-$1,112/month |
| Compounded telehealth price | $179-$314/mo (semaglutide) | $249-$399/mo (tirzepatide) |
| Cardiovascular indication | Yes (SELECT trial, March 2024) | Not yet (SURPASS-CVOT pending) |
| Supply status (May 2026) | Shortage resolved Feb 2025 | Shortage resolved Dec 2024 |
Sources: SURMOUNT-5 (NEJM, May 2025), STEP-1 (NEJM, 2021), SURMOUNT-1 (NEJM, 2022), FDA labels (May 2026), manufacturer pricing pages, and telehealth provider pricing as of May 2026.
The Key Difference: FDA Approval Status
This is the single most confusing aspect of the Wegovy vs Mounjaro comparison. They are often discussed as direct competitors, but they have different FDA-approved indications:
Wegovy (semaglutide)
- FDA-approved for chronic weight management (June 2021)
- FDA-approved for cardiovascular risk reduction (March 2024, SELECT trial)
- FDA-approved for MASH/NASH (liver disease, 2025)
- New 7.2mg high dose approved March 2026
Mounjaro (tirzepatide)
- FDA-approved for type 2 diabetes only (May 2022)
- NOT approved for weight loss (Zepbound is the weight-loss brand)
- Cardiovascular outcome trial (SURPASS-CVOT) still pending
- Widely prescribed off-label for weight loss by telehealth providers
Why this matters for insurance
If your insurance plan covers GLP-1s for weight loss, it will likely cover Wegovy (explicit weight-loss approval) or Zepbound (tirzepatide’s weight-loss label). Mounjaro is typically only covered for T2D. Some prescribers write Mounjaro off-label for weight loss, but this often requires a prior authorization fight. If you want tirzepatide for weight loss with the cleanest insurance path, ask for Zepbound, not Mounjaro.
How They Work: One Hormone vs Two
Both drugs mimic gut hormones released when you eat. They signal your brain that you are full and tell your pancreas to produce insulin. The critical difference is the number of hormone receptors each drug activates.
Wegovy — GLP-1 only
Semaglutide activates one receptor: GLP-1 (glucagon-like peptide-1). This suppresses appetite, slows gastric emptying, and increases insulin secretion after meals. Clinically significant on its own — STEP-1 showed -14.9% weight loss vs placebo — but a single-receptor approach.
Mounjaro — dual GLP-1 + GIP
Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The added GIP receptor amplifies post-meal insulin, further suppresses appetite, and may improve fat oxidation. This dual mechanism explains the 6.5 percentage-point advantage in head-to-head data.
Clinical Trial Data: SURMOUNT-5 Settles the Debate
Until May 2025, Wegovy and Mounjaro had never been tested head-to-head. Comparisons relied on cross-trial inference (STEP-1 vs SURMOUNT-1). The SURMOUNT-5 trial, published in the New England Journal of Medicine, finally gave a direct answer.
SURMOUNT-5
Tirzepatide vs Semaglutide (head-to-head)
STEP-1
Semaglutide 2.4mg (Wegovy dose)
STEP-5
Semaglutide 2.4mg (long-term maintenance)
SURMOUNT-1
Tirzepatide (Mounjaro/Zepbound doses)
What about the new Wegovy 7.2mg dose?
In March 2026, the FDA approved a higher 7.2mg dose of Wegovy for patients who have plateaued or need additional weight loss. The STEP-6 trial data (not yet published at the time of writing) is expected to show -17% to -18% weight loss at this higher dose — narrowing the gap with tirzepatide, though likely not closing it entirely based on the mechanism-of-action difference.
Side Effects: Wegovy vs Mounjaro
Both drugs share GI-dominant side effects. The recurring pattern across trials and user reports: Wegovy causes more nausea and vomiting, while Mounjaro causes slightly more constipation. Both improve dramatically with proper titration.
| Side Effect | Wegovy 2.4mg (STEP) | Mounjaro (SURMOUNT) |
|---|---|---|
| Nausea | ~44% | 24-33% |
| Diarrhea | ~30% | 19-23% |
| Vomiting | ~24% | 8-13% |
| Constipation | ~24% | 11-17% |
| Abdominal pain | Similar range | 9-10% |
| Discontinuation due to AEs | 4.5-5.6% | 4.3-7.1% |
Sources: STEP-1 (NEJM, 2021) for Wegovy side effects; SURMOUNT-1 (NEJM, 2022) for Mounjaro side effects. Trial populations and methodologies differ slightly.
Cost Comparison: May 2026 Pricing
Pricing has shifted in 2026 due to expanded manufacturer savings cards and the FDA’s April 30, 2026 proposal to exclude semaglutide and tirzepatide from the 503B compounding bulks list.
- Branded list price: ~$1,349/4 weeks
- NovoCare savings card: Drops cash price for qualifying patients
- Novo 50% cut: Announced $675 list effective Jan 2027
- Compounded semaglutide: $179-$314/mo via telehealth
- Insurance: Most commercial plans cover for weight loss; Medicare does NOT cover for weight loss alone
- Branded list price: ~$1,086-$1,112/month
- LillyDirect savings card: $199-$449/mo for qualifying patients
- Compounded tirzepatide: $249-$399/mo via telehealth
- Insurance (for T2D): Most commercial plans cover Mounjaro for type 2 diabetes
- Insurance (for weight): Need Zepbound label; Mounjaro off-label requires PA
Compounded GLP-1 status: May 2026
Both drug shortages have been resolved (tirzepatide Dec 2024, semaglutide Feb 2025). On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list. If finalized, only 503A patient-specific compounding (one Rx, one patient, one batch) remains legal. Large-scale 503B outsourcing facilities would be shut out.
Current compounded prices already reflect this uncertainty. If you are starting on compounded GLP-1, factor in that your pharmacy could be forced to stop during your treatment. Read our compounded GLP-1 guide for the full picture.
Which One Is Right For You?
Use this decision framework based on your situation.
Pick Wegovy if…
- Your insurance covers Wegovy for weight loss (most commercial plans do)
- You have cardiovascular risk factors and want the proven CV benefit (SELECT trial)
- You are cost-sensitive and going compounded (sema $179-$314 vs tirz $249-$399)
- You want the new 7.2mg high dose for additional weight loss
- You experienced GI distress (diarrhea/constipation) on tirzepatide
Pick Mounjaro if…
- You want the strongest average weight loss available (-20.2% in SURMOUNT-5)
- You have type 2 diabetes (Mounjaro is FDA-approved for this and insurance covers it)
- You tried Wegovy and plateaued — switching to tirzepatide breaks through for many patients
- Nausea was intolerable on semaglutide (Mounjaro has lower nausea rates: 24-33% vs 44%)
- You prefer the branded list price ($1,086 vs $1,349)
This is informational guidance, not medical advice. Your prescriber will consider additional factors (kidney function, gallbladder history, thyroid cancer risk, current medications, pregnancy plans) before recommending one over the other.
Where to Get Wegovy or Mounjaro via Telehealth
The telehealth providers below prescribe both semaglutide and tirzepatide (compounded, branded, or both). Pricing verified May 2026.
Telehealth Providers Offering Wegovy or Mounjaro
Pricing accurate as of May 2026. Click a provider to see current pricing and start a consultation. We may earn a commission — at no extra cost to you. See our affiliate disclosure.
| Provider | Monthly Price | Rating | Action |
|---|---|---|---|
SkinnyRxBest Overall 503A compounded GLP-1 specialistCompounded Tirzepatide + Semaglutide (503A pharmacy) | $199–$399 | ★★★★★4.9 | View Best Offer |
TrimRx Online weight loss program with GLP-1 medicationGLP-1 weight loss program (catalog VERIFY) | From $179/mo | ★★★★☆4.5 | View Best Offer |
MEDViEditor’s Pick Reliable mid-tier compounded GLP-1Compounded Tirzepatide + Semaglutide | $179–$299 | ★★★★☆4.6 | View Best Offer |
DirectMedsBest for Sublingual Sublingual + injectable compounded GLP-1Compounded Sema + Tirz (injectable + sublingual), Sermorelin, NAD+, Epithalon | $179–$399 | ★★★★☆4.5 | View Best Offer |
Ivim HealthBest for Microdosing 360 wellness — branded + compounded + microdosing GLP-1Compounded Sema/Tirz/Liraglutide, microdosing GLP-1, Wegovy/Zepbound/Mounjaro/Ozempic/Saxenda, Wegovy Pill | From $75/mo + $74.99 program fee | ★★★★☆4.7 | View Best Offer |
Eden HealthBest Value Branded + compounded with intro pricingCompounded Sema + Tirz, branded GLP-1, NAD+ (5 formats), Sermorelin, hormone therapy | $149 intro / $229–$249 ongoing | ★★★★☆4.7 | View Best Offer |
Sprout Health PENDING — URL not yet confirmedVERIFY | VERIFY | ☆☆☆☆☆0.0 | View Best Offer |
Elevate Health 3-month tirzepatide starter programCompounded Tirzepatide (2.5–15 mg/wk titration), Compounded Semaglutide | $299/mo or $897/3-mo bundle | ★★★★☆4.4 | View Best Offer |
OrderlyMeds Personalized GLP-1 + $3,700 value bundleCompounded Tirzepatide + Semaglutide, Wegovy, Zepbound | $149–$299 compounded, $1,498–$1,839 branded | ★★★★☆4.5 | View Best Offer |
GobyMeds Compounded GLP-1 with B12/NAD+ stack add-onsCompounded Sema + Tirz with B12/B6/NAD+/glycine combos, Wegovy, Zepbound, Sermorelin, NAD+ | From $99/mo (compounded sema) | ★★★★☆4.6 | View Best Offer |
Ro Largest US telehealth platformBranded (Wegovy, Zepbound) + select compounded | $149/mo + meds | ★★★★☆4.6 | View Best Offer |
Calibrate Coaching-led metabolic programBranded GLP-1s + 1:1 coaching + labs | $199/mo (3-month minimum) | ★★★★☆4.3 | View Best Offer |
Found Insurance-first weight-care platformBranded (insurance-billed) + compounded | ~$129/mo + meds | ★★★★☆4.2 | View Best Offer |
EmbodyBest Overall Flat $299/mo refills + GLP-1 gum (needle-free)Compounded Semaglutide + Tirzepatide (injectable + GLP-1 gum) | $149 first month / $299 flat refills | ★★★★★4.7 | View Best Offer |
Gala HealthBest for 3-Month Bundles All-inclusive 3-month GLP-1 bundles from $179–$199/moCompounded Semaglutide or Tirzepatide (GLP-1/GIP) | $179–$199/mo (3-month plan) | ★★★★☆4.5 | View Best Offer |
Care Bare RxBest Multi-Vertical Weight loss + hair + sexual health + NAD+ — discreet multi-careCompounded Semaglutide + Tirzepatide (oral + injectable) + hair + sexual health + NAD+ | From $199/mo (weight loss) | ★★★★☆4.4 | View Best Offer |
System LabsBest Value Lowest GLP-1 entry ($179/mo) + longevity stack — NAD+, B-12, sermorelinCompounded GLP-1 + NAD+ + B-12 + Sermorelin (oral + injectable) | GLP-1 $179/mo (lowest entry) | ★★★★☆4.5 | View Best Offer |
Strut Health No-video telehealth — GLP-1, hair, skin, ED + 2-day shippingCompounded Semaglutide + Tirzepatide, Hair Loss, Oral Sermorelin, Skin Care, ED | Oral Semaglutide from $99/mo, Oral Tirzepatide from $199/mo | ★★★★☆4.6 | View Best Offer |
TMatesBest Overall $158-$249/mo semaglutide, $167-$297/mo tirzepatide — same price all dosesCompounded Semaglutide + Tirzepatide (GLP-1), NAD+, TRT, ED, Skin Care, Hair Loss | Semaglutide $158-$249/mo, Tirzepatide $167-$297/mo (1-12 mo plans) | ★★★★☆4.7 | View Best Offer |
Pricing and availability current as of May 2026. We earn a commission if you sign up through our links — at no additional cost to you. See our methodology for how we evaluate providers.
Frequently Asked Questions
Is Mounjaro the same as Wegovy?+
No. Mounjaro contains tirzepatide (a dual GLP-1 + GIP receptor agonist made by Eli Lilly), while Wegovy contains semaglutide (a GLP-1-only receptor agonist made by Novo Nordisk). They are different molecules with different mechanisms of action. Mounjaro is FDA-approved for type 2 diabetes; its weight-loss counterpart is Zepbound. Wegovy is FDA-approved for chronic weight management and cardiovascular risk reduction.
Which causes more weight loss, Wegovy or Mounjaro?+
Mounjaro (tirzepatide) causes more weight loss on average. The SURMOUNT-5 head-to-head trial (NEJM, May 2025) directly compared both drugs at maximum tolerated doses for 72 weeks: tirzepatide produced -20.2% weight loss vs semaglutide -13.7% (P<0.001). That is approximately 14 pounds more loss on tirzepatide for someone starting at 220 lb.
Can I use Mounjaro for weight loss even though it is approved for diabetes?+
Mounjaro is FDA-approved only for type 2 diabetes. However, doctors can prescribe it off-label for weight loss, and many telehealth providers do exactly that. The FDA-approved weight-loss version of tirzepatide is called Zepbound (same molecule, same doses, different label). If your insurance covers Mounjaro for diabetes but not Zepbound for weight loss, some providers prescribe Mounjaro off-label.
How much does Wegovy cost vs Mounjaro in 2026?+
As of May 2026: Wegovy costs approximately $1,349 per 4-week supply at list price. Mounjaro costs approximately $1,086-$1,112 per month at list price. Both manufacturers offer savings cards: Eli Lilly LillyDirect drops Mounjaro/Zepbound to $199-$449/month; Novo Nordisk NovoCare offers comparable discounts on Wegovy. Compounded alternatives: semaglutide $179-$314/month, tirzepatide $249-$399/month via telehealth.
What are the side effects of Wegovy vs Mounjaro?+
Both drugs cause GI-dominant side effects. Wegovy (semaglutide 2.4mg) from STEP trials: nausea ~44%, diarrhea ~30%, vomiting ~24%, constipation ~24%. Mounjaro (tirzepatide) from SURMOUNT trials: nausea 24-33%, diarrhea 19-23%, constipation 11-17%, vomiting 8-13%. Pattern: Wegovy tends to cause more nausea and vomiting; Mounjaro tends to cause slightly more constipation. Both improve with slow titration every 4 weeks as per FDA labeling.
Can I switch from Wegovy to Mounjaro?+
Yes. Many patients switch after plateauing on Wegovy. Standard practice is to stop Wegovy for one weekly cycle, then start Mounjaro at 2.5mg and titrate up every 4 weeks. Because they are different molecules (semaglutide vs tirzepatide), there is no cross-tolerance concern. Always switch under prescriber supervision to manage GI side effects during the transition.
Related Comparison Guides
Editorial note: This page is reviewed against primary clinical-trial sources (NEJM publications) and current FDA labeling. Pricing data was verified May 3, 2026 from manufacturer pricing pages and telehealth provider sites. FDA approval dates and indications verified against FDA.gov drug labels.
Not medical advice. Always consult a licensed prescriber before starting, switching, or stopping any GLP-1 medication.
Related Guides
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
Related Guides
Continue your research with these related independent reviews.